The News: Now that we’ve reached the end of the first half of 2018, there might be some interesting surprises–both good and not-so-good–for those equity investors interested in who’s being… Read more »
The News: It has long been a controversial theory about Alzheimer’s disease (AD), often dismissed by experts as a random detour from mainstream research. But a new study by a team that… Read more »
The News: Last week the Nasdaq Biotech Index swooned 4% on Wednesday (July 27, 2018), only to rebound and halve that downdraft by Friday’s close (July 29, 2018). But despite… Read more »
In recent years, biotech IPOs came one, or maybe two, most weeks. But in 2018, things are very different. Last week, a mind boggling eight were priced, simultaneously testing investors’ appetite… Read more »
The News: Two Chinese biotechs recently scrapped plans to list in New York and instead aim to raise up to $800 million in Hong Kong IPOs, seeking to cash in… Read more »
The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »
The News: The 2018 America Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 1-5 in Chicago, brought together more than 32,000 oncology professionals from around the world to… Read more »
The News: With the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, startup Cortexyme Inc. (South San Francisco) has identified a brand-new target and… Read more »
A European decision to exclude Britain from the EU’s drug approval system from beginning 30, 2019–the day after Brexit–has raised alarm among drugmakers, who fear the abrupt change could disrupt… Read more »
In all my 26 years at MondayMorning, never have I witnessed such a massive, mad dash for the IPO filing window, and the SEC must be wondering if and when… Read more »
